{
    "clinical_study": {
        "@rank": "74050", 
        "arm_group": [
            {
                "arm_group_label": "Canagliflozin 100 mg", 
                "arm_group_type": "Experimental", 
                "description": "Each participant will receive 100 mg of canagliflozin once daily for 18 weeks."
            }, 
            {
                "arm_group_label": "Canagliflozin 300 mg", 
                "arm_group_type": "Experimental", 
                "description": "Each participant will receive 300 mg of canagliflozin once daily for 18 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Each participant will receive matching placebo once daily for 18 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effects of administration of canagliflozin 100 mg\n      and 300 mg, compared with placebo as an addition to insulin therapy for the treatment of\n      Type 1 Diabetes Mellitus (T1DM)."
        }, 
        "brief_title": "A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 1", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized (the study medication is assigned by chance), double-blind (neither\n      physician nor participant knows the identity of the assigned treatment), placebo-controlled\n      (an inactive substance that is compared with a medication to test whether the medication has\n      a real effect) parallel-group, multicenter study of canagliflozin as an addition to insulin\n      therapy for participants with type 1 diabetes mellitus and inadequate glycemic control.\n\n      Approximately 330 participants will be randomly assigned in a 1:1:1 ratio to either\n      canagliflozin 100 mg, canagliflozin 300 mg, or placebo groups. About 90 participants (30 per\n      treatment group) will be selected for a substudy with a purpose of a continuous glucose\n      monitoring (CGM) assessment for 7 days at baseline and 7 days at the end of treatment.\n\n      The total duration of the participation will be about 22 weeks, during which participants\n      will need to return to investigational sites for approximately 9 visits. During the study\n      participants will receive advice on treatment of hypoglycemia and diabetic ketoacidosis\n      (DKA), as well as on compliance with diet and exercise."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have type 1 diabetes mellitus (T1DM) for at least 1 year\n\n          -  Must have have inadequate glycemic control (as defined by glycosylated hemoglobin\n             level of >= 7.0% to <= 9.0%) on basal plus bolus insulin at screening\n\n          -  Must have body mass index 21 to 35 kg/m2 inclusive\n\n          -  Must be on a total daily dose of insulin >= 0.6 IU/kg at screening\n\n          -  Must be on a stable insulin regimen for at least 8 weeks prior to screening\n\n        Exclusion Criteria:\n\n          -  History of T2DM, pancreas or \u03b2-cell transplantation, or diabetes secondary to\n             pancreatitis or pancreatectomy\n\n          -  Severe hypoglycemia (defined as an event required assistance from another person, or\n             which resulted in seizure or loss of consciousness) within 6 months prior to study\n             start\n\n          -  Diabetic ketoacidosis within 6 months prior to study start\n\n          -  History of hereditary glucose-galactose malabsorption or primary renal glycosuria\n\n          -  An ongoing, inadequately controlled thyroid disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "330", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02139943", 
            "org_study_id": "CR104173", 
            "secondary_id": "2013-005078-24"
        }, 
        "intervention": [
            {
                "arm_group_label": "Canagliflozin 100 mg", 
                "description": "Canagliflozin capsule of 100 mg dose will be taken orally, before the first meal of the day.", 
                "intervention_name": "Canagliflozin 100 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Canagliflozin 300 mg", 
                "description": "Canagliflozin capsule of 300 mg dose will be taken orally, before the first meal of the day.", 
                "intervention_name": "Canagliflozin 300 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Matching placebo capsule will be taken orally, before the first meal of the day.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Diabetes Mellitus, Type 1", 
            "Canagliflozin", 
            "Continuous Glucose Monitoring"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas"
                }
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects With Type 1 Diabetes Mellitus", 
        "overall_contact": {
            "email": "JNJ.CT@sylogent.com", 
            "last_name": "This study is not yet recruiting patients. Please check back for future recruiting sites, or email"
        }, 
        "overall_official": {
            "affiliation": "Janssen Research & Development, LLC", 
            "last_name": "Janssen Research & Development, LLC Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of participants with hemoglobin A1c (HbA1c) reduction >=0.4% and no increase in body weight", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 18"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02139943"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of adverse events as a measure of safety and tolerability", 
            "safety_issue": "No", 
            "time_frame": "Baseline, up to Week 18"
        }, 
        "source": "Janssen Research & Development, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}